An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS<sup>® </sup>hydromorphone in patients with chronic cancer pain
<p>Abstract</p> <p>Background</p> <p>Opioid analgesics have proven efficacy in the short-term management of chronic cancer pain, but data on their long-term use is more limited. OROS<sup>® </sup>hydromorphone is a controlled-release formulation of oral hydro...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-09-01
|
| Series: | BMC Palliative Care |
| Online Access: | http://www.biomedcentral.com/1472-684X/8/14 |